<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fingolimod</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08868</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Fingolimod is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08868/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08868/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08868.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08868.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08868.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08868.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08868.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08868">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fingolimod Hydrochloride</strong>
          <div class="cas">162359-56-0</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000580/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000580/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: SWZTYAVBMYWFGS-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 343.227807044</li>
              <li>Average Mass: 343.932</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000580">DBSALT000580</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Gilenia</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Gilenya</td><td>Novartis Pharmaceuticals Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>162359-55-9</td></tr><tr><th>Weight</th><td>Average: 307.4708<br>Monoisotopic: 307.251129305</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>33</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>KKGQTZUTZRNORY-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylpropylamines</td></tr><tr><th>Direct parent</th><td>Phenylpropylamines</td></tr><tr><th>Alternative parents</th><td>1,2-Aminoalcohols; Polyols; Polyamines; Primary Alcohols; Monoalkylamines</td></tr><tr><th>Substituents</th><td>1,2-aminoalcohol; polyol; primary alcohol; polyamine; amine; primary amine; primary aliphatic amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.</td></tr><tr><th>Pharmacodynamics</th><td>Fingolimod causes a transient reduction in heart rate and AV conduction at treatment initiation.
Potential to prolong the QT interval.
Effects on immune cell numbers in the blood- decreased lymphocyte counts.
Mild decrease in the neutrophil count- about 80% of original pre-therapy count.
Compared to placebo, antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV, respectively.
IgG titers were decreased by 45% and 50%, in response to KLH and PPV.
The capacity to mount a skin delayed-type hypersensitivity reaction to Candida and tetanus toxoid was decreased by approximately 30% in subjects on fingolimod 0.5 mg daily, compared to placebo. Immunologic responses were further decreased with fingolimod 1.25 mg (a dose higher than recommended for MS).
Single fingolimod doses &#8805;5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance. </td></tr><tr><th>Mechanism of action</th><td>Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. </td></tr><tr><th>Absorption</th><td>The Tmax of fingolimod is 12-16 hours. 
Bioavailability: 93% </td></tr><tr><th>Volume of distribution</th><td><p>about 1200&#177;260 L.</p></td></tr><tr><th>Protein binding</th><td>&gt;99.7%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>3 main pathways: 
-reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod-phosphate.
-oxidative biotransformation mainly via the cytochrome P450 4F2 isoenzyme and subsequent fatty acid-like degradation to inactive metabolites.
-by formation of pharmacologically inactive non-polar ceramide analogs of fingolimod.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>6-9 days</td></tr><tr><th>Clearance</th><td><p>Fingolimod blood clearance is 6.3&#177;2.3 L/h.</p></td></tr><tr><th>Toxicity</th><td>Bradyarrhythmia and Atrioventricular Blocks
Risk of infections
Macular Edema
Respiratory Effects
Hepatic Effects  
Fetal Risk
Blood Pressure Effects
Immune System Effects Following Fingolimod Discontinuation</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9884</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5779</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5055</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6975</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9505</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9391</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.823</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8251</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6702</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7685</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5519</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8526</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.6567</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8152</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7348</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8945</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8647
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8562
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9062
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9996 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.933
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7302
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>0.5mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. </td></tr><tr><td><a href="/drugs/DB08879">Belimumab</a></td><td>Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. </td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. </td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. </td></tr><tr><td><a href="/drugs/DB00308">Ibutilide</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>